Ketoconazole

Introduction Overview

Generic Name

Ketoconazole

Brand Name

Ketoconazole Cream

Dosage Form

Topical cream

Drug Class

Topical antifungals

Pharmacokinetics

Absorption:
Ketoconazole cream, 2%, when applied topically to intact or abraded skin, demonstrates minimal systemic absorption. In studies conducted on beagle dogs applying 80 mg daily for 28 days, plasma levels of ketoconazole were undetectable using assays with sensitivity to 2 ng/mL. Similarly, in human volunteers receiving topical application over large surface areas (chest, back, arms), ketoconazole was not measurable in blood at levels greater than 5 ng/mL over 72 hours post-application. This limited absorption indicates a primarily local effect with negligible systemic exposure, reducing systemic side effect risks associated with oral formulations.

Distribution:
Due to minimal systemic absorption, ketoconazole distributes predominantly within the superficial layers of the skin at the site of application. The drug integrates into the stratum corneum and epidermis, where it exerts its antifungal action. The cream's formulation with excipients like propylene glycol and isopropyl myristate facilitates penetration into the skin layers but does not lead to significant systemic distribution. There is no evidence of accumulation in distant tissues or systemic compartments after topical application.

Metabolism:
Topically applied ketoconazole undergoes limited metabolism owing to negligible systemic entry. Unlike orally administered ketoconazole, which undergoes substantial hepatic metabolism via cytochrome P450 enzymes, the topical formulation avoids first-pass hepatic metabolism. The minimal systemic exposure also reduces the risk of hepatotoxic metabolites and associated systemic toxicities. Dermal metabolism, if any, is presumed to be minimal and localized, possibly by skin enzymes, but this has not been extensively characterized.

Elimination:
Given the low systemic absorption, elimination pathways involve minimal systemic clearance via hepatic metabolism and renal excretion. Most of the applied ketoconazole is likely cleared from the skin surface and stratum corneum through natural desquamation and wash-off. The drug's elimination half-life in systemic circulation following topical use is not clinically relevant due to its minimal systemic bioavailability. This pharmacokinetic profile supports the topical cream’s safety for localized fungal infections without systemic drug accumulation.

Dosage Forms

Available Dosage Forms:
Ketoconazole is formulated as a 2% topical cream designed for cutaneous application. The cream is white to off-white in color and contains 20 mg of ketoconazole per gram of cream. It is supplied in tubes of 15 g, 30 g, and 60 g. The formulation includes excipients such as butylated hydroxyanisole (BHA), cetyl alcohol, isopropyl myristate, polysorbate 60 and 80, propylene glycol, purified water, sorbitan monostearate, and stearyl alcohol, which optimize stability, skin penetration, and patient tolerance.

Dosages for Adults and Adolescents:
For the treatment of cutaneous candidiasis, tinea corporis, tinea cruris, and tinea pedis, the recommended dose is once daily topical application of ketoconazole 2% cream to the affected area and immediately surrounding skin. The duration varies by condition: two weeks for candidiasis and tinea cruris/corporis, six weeks for tinea pedis, and two weeks for tinea (pityriasis) versicolor.
For seborrheic dermatitis, application is recommended twice daily for four weeks or until clinical resolution.
Dosing regimens have been established from clinical trials which support effectiveness with these durations, balancing efficacy with patient compliance.

Specific Patient Populations:
Use in pediatric populations has not established safety and efficacy; therefore, use is not recommended without clinical justification. In pregnant women, ketoconazole is categorized as Pregnancy Category C; topical use should only be considered if benefits outweigh risks. Lactating mothers should use caution due to unknown secretion into breast milk and potential systemic exposure.
Elderly patients have not shown altered dosing requirements due to minimal systemic absorption. No dosage adjustments are necessary in renal or hepatic impairment given the topical route and low systemic exposure.

Storage and Handling:
Ketoconazole cream should be stored at controlled room temperature between 20°-25°C (68°-77°F). Tubes should be kept tightly closed and protected from excessive heat or freezing. The cream is for dermatologic use only and must not be used in the eyes or mucous membranes.

Mechanism Of Action

Ketoconazole cream exerts its antifungal activity primarily through inhibition of fungal ergosterol synthesis, a vital component of fungal cell membranes. Ketoconazole targets and inhibits the cytochrome P450-dependent enzyme lanosterol 14-alpha-demethylase, which catalyzes the demethylation of lanosterol to ergosterol. The resulting ergosterol depletion disrupts fungal cell membrane integrity, leading to increased membrane permeability and leakage of essential intracellular components.

On a molecular level, ketoconazole binds to the heme iron of the lanosterol 14-alpha-demethylase, preventing the normal enzymatic conversion necessary for ergosterol biosynthesis. This disturbance impedes fungal growth and replication by compromising membrane fluidity and function. The drug primarily affects dermatophytes and yeasts responsible for common superficial fungal infections.

At the cellular pathway level, inhibition of ergosterol synthesis also leads to accumulation of toxic 14-alpha-methyl sterols within the fungal cell, further impairing membrane-dependent enzymes and nutrient transport processes. This dual effect both inhibits fungal proliferation and promotes fungal cell death.

Clinically, the reduction of Malassezia species populations on the skin accounts for ketoconazole’s therapeutic benefit in seborrheic dermatitis, although the exact contribution remains less well defined. Compared to other azole antifungals, ketoconazole shares this common mechanistic pathway but has a broader antifungal spectrum with activity against both dermatophytes and some yeasts.

Extensive in vitro and clinical studies have substantiated ketoconazole’s ability to effectively clear fungal infections with topical administration, demonstrating both fungistatic and fungicidal properties depending on fungal species and concentration. Resistance development is rare due to the drug's mechanism targeting essential cell membrane synthesis.

Pharmacological Actions

Broad-spectrum antifungal activity against dermatophytes including Trichophyton and Epidermophyton species.
Antifungal activity against yeasts such as Candida albicans and Malassezia species responsible for tinea versicolor and seborrheic dermatitis.
Inhibition of ergosterol biosynthesis, leading to impaired fungal cell membrane synthesis and function.
Fungistatic and fungicidal effects depending on fungal species and concentration.
Topical formulation limits systemic absorption while delivering high local concentrations at affected skin sites.
Demonstrates minimal skin irritation, sensitization, and phototoxic reactions based on clinical safety studies.
Reduces fungal load and symptoms such as inflammation, pruritus, and scaling associated with superficial mycoses.
Improves clinical signs in seborrheic dermatitis by reducing Malassezia colonization.
Does not demonstrate significant systemic immunosuppressive effects due to minimal absorption.
Exhibits negligible interaction with systemic cytochrome P450 enzymes from topical administration.

Therapeutic Or Clinical Uses

Topical treatment of tinea corporis (ringworm) caused by Trichophyton rubrum, T. mentagrophytes, and Epidermophyton floccosum.
Management of tinea cruris (jock itch) infections of the groin area caused by dermatophytes.
Treatment of tinea pedis (athlete’s foot), including interdigital and plantar infections.
Therapy for pityriasis versicolor (tinea versicolor) caused by Malassezia furfur.
Topical treatment of cutaneous candidiasis caused by Candida species.
Management of seborrheic dermatitis by reducing Malassezia colonization and associated inflammation.
Use for dermatologic fungal infections where oral antifungal drugs are contraindicated or not tolerated.
Alternative therapy in patients with mild to moderate fungal skin infections requiring localized treatment.
Adjunctive therapy in dermatologic conditions complicated by fungal colonization or superinfection.

Side Or Adverse Effects

Localized skin irritation including burning, stinging, and redness at the application site.
Pruritus (itching) reported in a minority of patients following topical application.
Rare allergic contact dermatitis manifesting as painful allergic reactions.
Rare reports of contact dermatitis related to excipients such as propylene glycol in the cream formulation.
No systemic adverse effects noted due to negligible systemic absorption.
No phototoxic or photoallergic reactions reported in clinical studies.
Potential for mild skin dryness or peeling with prolonged use.
Low incidence of hypersensitivity reactions; patients should discontinue use if sensitivity develops.
Rare exacerbation of seborrheic dermatitis symptoms during initial treatment phase.
No evidence of systemic hormonal effects or hepatic toxicity with topical ketoconazole.

Precautions

Discontinue use if signs of sensitivity, chemical irritation, or allergic reactions occur.
Avoid application on mucous membranes and ophthalmic areas to prevent irritation or toxicity.
Use cautiously in patients with known allergies to ketoconazole or cream excipients (e.g., propylene glycol).
Monitor pregnant patients carefully; use only if benefits justify potential risks (Pregnancy Category C).
Nursing mothers should decide on drug discontinuation or cessation of nursing considering potential risks.
Safety and effectiveness not established in pediatric patients; use only if clearly indicated.
Do not use on broken skin or open wounds without physician approval due to lack of safety data.
Avoid concomitant use with other topical products at the application site to minimize irritation.
Patients should be instructed on proper hygiene and application technique to enhance treatment efficacy.
Long-term safety data for topical use beyond recommended durations is limited; avoid prolonged use.
Inform patients about potential mild local side effects to improve adherence and early identification.

Warnings

Ketoconazole cream is strictly for dermatologic use and must not be used for ophthalmic purposes.
Hypersensitivity or allergic reactions necessitate immediate discontinuation of the medication.
Systemic toxicity associated with oral ketoconazole (e.g., hepatotoxicity, hormonal alterations) has not been observed with topical cream.
Potential for skin irritation or contact dermatitis in susceptible individuals; monitor application sites regularly.
Use caution in patients with extensive skin damage or infections that might increase absorption.
Avoid application to open wounds or severely inflamed skin unless directed by a healthcare provider.
Not intended for use in systemic fungal infections; inappropriate use could delay definitive treatment.
Concurrent use with corticosteroids or other immunosuppressive agents should be supervised to prevent adverse skin reactions.
In absence of clinical improvement following recommended treatment duration, reassessment of diagnosis is advised.
Keep out of reach of children to prevent accidental ingestion or misuse.

Contraindication

Known hypersensitivity or allergic reactions to ketoconazole or any excipients in the cream formulation.
Use is contraindicated in patients with prior sensitization to topical antifungal agents containing imidazole derivatives.
Not to be applied to ophthalmic tissues or mucous membranes.
Avoid use in individuals with severe skin conditions where infection or irritation might be exacerbated by topical agents.
Contraindicated in patients with a history of chemical irritation upon application of ketoconazole cream.

Drug Interactions

Due to minimal systemic absorption, ketoconazole cream has negligible potential for systemic drug interactions.
No significant interaction with systemic cytochrome P450 substrates when used topically.
Concurrent topical agents applied to the same site may alter absorption or efficacy; separate application times recommended.
Avoid simultaneous use with topical corticosteroids unless prescribed for combined therapy, to monitor for additive skin effects.
Interactions with systemic antifungals or systemic medications are unlikely with topical use but caution is advised if combined.
Patients should inform healthcare providers about all topical and systemic medications to mitigate possible local interactions.
No documented interaction with antibiotics or antivirals when used topically.
No known effects on efficacy of vaccines or immunizations.
Ketoconazole cream does not interfere with hormonal contraceptives or anticoagulant therapies when used topically.
No interaction noted with dermatologic emollients or moisturizers.

Preparations Of The Drug

Ketoconazole Cream 2%: A white to off-white cream containing 20 mg of ketoconazole per gram of formulation.
Available in tubes of 15 g, 30 g, and 60 g packaged individually in cartons.
Contains excipients including butylated hydroxyanisole (BHA), cetyl alcohol, isopropyl myristate, polysorbate 60, polysorbate 80, propylene glycol, purified water, sorbitan monostearate, and stearyl alcohol to enhance stability and skin permeability.
Non-combination topical formulation intended exclusively for antifungal dermatologic use.
Supplied by Golden State Medical Supply, Inc., manufactured by Taro Pharmaceuticals Inc.
The cream is for prescription use only and stored at controlled room temperature (20-25°C).
No additional preservatives that commonly cause sensitization to reduce irritation risk.
Formulated to have low potential for phototoxic or photoallergic reactions.
Available as a human prescription drug under the product labeling NDC codes 51407-279-15, 51407-279-30, and 51407-279-60.
Supplied in differentiable tube sizes to accommodate short or extended treatment courses.
Packaged with labeling specifying usage instructions, storage conditions, and 'FOR DERMATOLOGIC USE ONLY' warnings.